MYC and neoplasm: Both the canonical (EZH2-PRC2) and noncanonical (EZH2-TAD-Myc-coactivators) functions of EZH2 contribute to oncogenesis, elucidating the limited and gradual efficacy of inhibitors targeting EZH2’s catalytic function in anti-tumor effects (Table 1) [37,42].